RU2015132977A - Нафтиридиноновые производные и их применение в лечении, уменьшении интенсивности или профилактике вирусного заболевания - Google Patents

Нафтиридиноновые производные и их применение в лечении, уменьшении интенсивности или профилактике вирусного заболевания

Info

Publication number
RU2015132977A
RU2015132977A RU2015132977A RU2015132977A RU2015132977A RU 2015132977 A RU2015132977 A RU 2015132977A RU 2015132977 A RU2015132977 A RU 2015132977A RU 2015132977 A RU2015132977 A RU 2015132977A RU 2015132977 A RU2015132977 A RU 2015132977A
Authority
RU
Russia
Prior art keywords
alkyl
compound
optionally substituted
general formula
group
Prior art date
Application number
RU2015132977A
Other languages
English (en)
Russian (ru)
Other versions
RU2015132977A3 (enExample
Inventor
Андреа ВОЛЬКЕРШТОРФЕР
Оливер СЦОЛАР
Норберт Хандлер
Хельмут БУШМАНН
Стефен Кьюсак
Марк СМИТ
Сунг-Сау СО
Роланд Чарльз ХОУЛИ
Ачьютарао Сиддури
Original Assignee
Савира Фармасьютикалз Гмбх
Ф. Хоффманн-Ля Рош Аг
Юропиан Молекьюлар Байолоджи Лаборатори
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Савира Фармасьютикалз Гмбх, Ф. Хоффманн-Ля Рош Аг, Юропиан Молекьюлар Байолоджи Лаборатори filed Critical Савира Фармасьютикалз Гмбх
Publication of RU2015132977A publication Critical patent/RU2015132977A/ru
Publication of RU2015132977A3 publication Critical patent/RU2015132977A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2015132977A 2013-01-08 2014-01-07 Нафтиридиноновые производные и их применение в лечении, уменьшении интенсивности или профилактике вирусного заболевания RU2015132977A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750032P 2013-01-08 2013-01-08
US61/750,032 2013-01-08
PCT/EP2014/050168 WO2014108408A1 (en) 2013-01-08 2014-01-07 Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (2)

Publication Number Publication Date
RU2015132977A true RU2015132977A (ru) 2017-02-14
RU2015132977A3 RU2015132977A3 (enExample) 2017-12-28

Family

ID=50073147

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015132977A RU2015132977A (ru) 2013-01-08 2014-01-07 Нафтиридиноновые производные и их применение в лечении, уменьшении интенсивности или профилактике вирусного заболевания

Country Status (12)

Country Link
US (3) US9199987B2 (enExample)
EP (1) EP2945945B1 (enExample)
JP (1) JP2016504376A (enExample)
KR (1) KR20150103672A (enExample)
CN (1) CN104903319B (enExample)
BR (1) BR112015013414A2 (enExample)
CA (1) CA2894821A1 (enExample)
ES (1) ES2597803T3 (enExample)
HK (1) HK1211288A1 (enExample)
MX (1) MX2015008292A (enExample)
RU (1) RU2015132977A (enExample)
WO (1) WO2014108408A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709321A (zh) 2015-04-28 2018-02-16 盐野义制药株式会社 经取代的多环性吡啶酮衍生物及其前药
HK1254961A1 (en) 2015-12-15 2019-08-02 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
US10759814B2 (en) 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JP2020176263A (ja) * 2019-04-19 2020-10-29 住友化学株式会社 フィルム及び農園芸用施設

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
EP2231665A4 (en) * 2008-01-07 2012-04-25 Ardea Biosciences Inc NEW COMPOSITIONS AND METHODS OF USE
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
WO2011041143A1 (en) * 2009-10-01 2011-04-07 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

Also Published As

Publication number Publication date
BR112015013414A2 (pt) 2017-07-11
US9199987B2 (en) 2015-12-01
ES2597803T3 (es) 2017-01-23
JP2016504376A (ja) 2016-02-12
EP2945945B1 (en) 2016-08-31
CN104903319A (zh) 2015-09-09
HK1211288A1 (en) 2016-05-20
CN104903319B (zh) 2017-05-31
US9505758B2 (en) 2016-11-29
US20140194432A1 (en) 2014-07-10
US20170290834A1 (en) 2017-10-12
MX2015008292A (es) 2016-06-02
US20160039818A1 (en) 2016-02-11
WO2014108408A1 (en) 2014-07-17
KR20150103672A (ko) 2015-09-11
EP2945945A1 (en) 2015-11-25
CA2894821A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
RU2015125570A (ru) Пиридоновые производные и их применение в лечении, уменьшении интенсивности симптомов или предотвращении вирусного заболевания
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2016518305A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2014143250A (ru) Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания
RU2014120421A (ru) Производные гетероарилгидроксамовой кислоты и их применение при лечении, облегчении течения или профилактике вирусных заболеваний
JP2015517555A5 (enExample)
MX2022003032A (es) Oxinitruro de piridina, metodo para su preparacion y uso de este.
RU2014120477A (ru) Производные пиримидин-4-она и их применение в лечении, облегчении или профилактике вирусного заболевания
HRP20200538T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20241540T1 (hr) Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
JP2014530837A5 (enExample)
JP2016508145A5 (enExample)
JP2010536887A5 (enExample)
EA200970670A1 (ru) Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
RU2018105549A (ru) Производные бензодиазепина как ингибиторы rsv
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
JP2017518959A5 (enExample)
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
RU2014115796A (ru) Модуляторы ror-гамма
EP4606427A3 (en) Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof
JP2019510034A5 (enExample)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2018502101A5 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180411